Shanghai Raas Blood Products

What Shanghai Raas Blood Products does

Shanghai RAAS Blood Products Co., Ltd. is a leading Chinese blood products manufacturer founded in 1988 and listed on the Shenzhen Stock Exchange (stock code: 002252) since June 2008. The company operates a vertically integrated platform spanning 55 plasma donation centers across 11 provinces and 6 production bases located in Shanghai, Hefei, Zhengzhou, Wenzhou, Nanning, and Hengyang. Its core technology stack is built on blood plasma fractionation and purification, nucleic acid amplification testing (NAT/TMA) for pathogen screening, virus inactivation/removal methods, and recombinant protein drug development. The product portfolio comprises 12 plasma-derived products organized into three categories: albumin (ALBURAAS/安普莱士), immunoglobulins (GAMARAAS/伽玛莱士), and coagulation factors including Factor VIII (HEMORAAS/海莫莱士), prothrombin complex (PROTHORAAS/普舒莱士), fibrinogen (FIBRORAAS/法布莱士), fibrin sealant (FIBINGLURAAS/护固莱士), and thrombin (THROMBIRAAS/舒平莱士). Human fibrinogen market share ranks #1 in China; 2024 plasma collection exceeded 1,600 tons with multi-year growth.

The company generates revenue through direct sales of blood products to public and private hospitals and medical institutions across China via government tendering and public procurement processes, with pricing subject to National Basic Medical Insurance Drug Catalog negotiations. A secondary revenue stream is the exclusive mainland China distribution of Grifols' Procleix NAT product portfolio (HIV-1/2, HCV, HBV screening). In 2024, Shanghai RAAS reported revenue of RMB 8.176 billion with net profit of RMB 2.193 billion (+23.25% YoY). In June 2024, Haier Group acquired a 20% equity stake for RMB 12.5 billion through Haiyingkang Medical Technology, gaining 26.58% voting rights and becoming the actual controller, integrating Shanghai RAAS into the Haier One Health Ecosystem (盈康一生). Grifols retained a 6.58% stake and board seat, with the existing albumin distribution agreement extended for up to 20 years. The innovation pipeline includes SR604, a globally first-in-class activated protein C monoclonal antibody for hemophilia developed with Boehringer-Ingelheim CDMO support, currently in Phase II clinical trials.

Customers are Chinese public and private hospitals and clinics procuring products for hypoproteinemia, immune deficiency, hemophilia, surgical bleeding, and factor deficiency treatments. Marketing channels are predominantly institutional — medical and academic conferences (e.g., World Federation of Hemophilia Congress, CIIE), government and industry awards, Shenzhen Stock Exchange investor disclosures, and WeChat/corporate website. The company's "expand plasma" (拓浆) and "de-plasma" (脱浆) dual-track strategy targets raw material supply growth and innovative biologics development, respectively, with 2024 R&D investment of RMB 251 million (+44.42% YoY) and 120 granted patents (domestic and international) plus 37 software copyrights.

Name

Shanghai Raas Blood Products

Legal name

Shanghai RAAS Blood Products Co., Ltd. (上海莱士血液制品股份有限公司)

Website

http://www.raas-corp.com/

Company type

Public

Founded year

1988

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Shanghai RAAS is a leading Chinese blood products manufacturer with 55 plasma donation centers across 11 provinces and 6 production bases, producing albumin, immunoglobulins, and coagulation factors for hospitals and medical institutions. Now controlled by Haier Group, it is also developing SR604, a first-in-class hemophilia monoclonal antibody.

Ownership category

akta.pro rank

Product category

Blood Plasma Products (Biopharmaceuticals)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Plasma Fractionation & Purification Manufacturing (HLAIAHAI)

akta.pro secondary industries

Plasma-Derived Coagulation Factors (Hemophilia Therapies) (HLAIAHAB), Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI), Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics) (HLAAAAAL), Plasma Collection & Donor Services (Plasmapheresis Centers) (HLAIAHAH)

Keywords

• Blood plasma products
• Plasma fractionation
• Biopharmaceutical manufacturing
• Immunoglobulin therapy
• Coagulation factor products

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Blood Product Sales (Albumin, Immunoglobulins, Coagulation Factors): Shanghai RAAS manufactures and sells blood products including human albumin (安普莱士), intravenous immunoglobulin (伽玛莱士), human coagulation factor VIII (海莫莱士), human fibrinogen (法布莱士), human fibrin sealant (护固莱士), human thrombin (舒平莱士), and prothrombin complex (普舒莱士). Revenue is generated through direct sales to hospitals and medical institutions across China.
2. Exclusive Distribution of Grifols NAT Products: Shanghai RAAS serves as the exclusive distributor of Grifols' Procleix nucleic acid testing product portfolio in mainland China (excluding Taiwan, Hong Kong, and Macau), importing and selling Grifols' NAT platforms and consumables for blood and plasma screening.
3. Innovative Drug Pipeline (SR604 and others): Through its 'de-plasma' (脱浆) strategy, Shanghai RAAS is developing innovative biologics including SR604 injection for hemophilia, with Boehringer-Ingelheim providing CDMO services for clinical manufacturing, potentially creating new revenue streams as products reach market.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Shanghai RAAS manufactures and sells human blood plasma-derived products, including human albumin, intravenous immunoglobulin (IVIG), coagulation factor VIII, prothrombin complex, human fibrinogen, fibrin sealant, and human thrombin, distributed to hospitals and medical institutions across China. The company also operates a network of 55 plasma donation centers across 11 provinces that supply raw plasma, and is developing innovative biologics such as SR604, a first-in-class monoclonal antibody for hemophilia treatment.

Product overview

Shanghai RAAS is a leading Chinese blood products company offering a comprehensive portfolio organized into three main categories: Albumin (ALBURAAS®/安普莱士®), Immunoglobulins (GAMARAAS®/伽玛莱士®), and Coagulation Factors (HEMORAAS®/海莫莱士®, PROTHORAAS®/普舒莱士®, FIBRORAAS®/法布莱士®, FIBINGLURAAS®/护固莱士®, THROMBIRAAS®/舒平莱士®). The company operates as a platform with multiple sub-brands including Tonrol Biopharmaceutical (同路生物), Zhengzhou RAAS (郑州莱士), Zhejiang Haikang (浙江海康), and Nanyue Biopharmaceutical (南岳生物). In addition to traditional plasma-derived products, Shanghai RAAS is developing innovative biologics including SR604, a first-in-class monoclonal antibody for hemophilia treatment. The company maintains 55 plasma donation centers across 11 provinces and 6 production bases.

Differentiator

Problem solved

Functional benefit

Brands

• SR604: Globally innovative monoclonal antibody drug for hemophilia and congenital factor VII deficiency; targets activated protein C; entered Phase I/II clinical trials and is preparing for Phase III. No same-target product marketed globally.
• 安普莱士 (Albumin RAAS / ALBURAAS)
• 伽玛莱士 (GAMARAAS)
• 海莫莱士 (HEMORAAS)
• 法布莱士 (FIBRORAAS)
• 护固莱士 (FIBINGLURAAS)
• 舒平莱士 (THROMBIRAAS)
• 普舒莱士 (PROTHORAAS)

Products and services

• ALBURAAS® (安普莱士®) - Human Albumin Human albumin product prepared from plasma, used for volume replacement and treatment of hypoalbuminemia, burns, shock, and related conditions. Sold to hospitals and medical institutions for clinical use.
• GAMARAAS® (伽玛莱士®) - Human Immunoglobulin (pH4) for Intravenous Injection (IVIG) Intravenous immunoglobulin product for treatment of immune deficiencies and certain autoimmune conditions. Sold to hospitals and clinics.
• HEMORAAS® (海莫莱士®) - Human Coagulation Factor VIII Clotting factor concentrate for treatment and prevention of bleeding in hemophilia A patients. Distributed to hospitals and medical institutions.
• PROTHORAAS® (普舒莱士®) - Human Prothrombin Complex Concentrate (PCC) Prothrombin complex concentrate containing clotting factors II, VII, IX, and X for treatment of bleeding disorders. Sold to hospitals and clinics.
• FIBRORAAS® (法布莱士®) - Human Fibrinogen Fibrinogen concentrate for treatment of hypofibrinogenemia and bleeding conditions. Holds the #1 market share in China's fibrinogen industry.
• FIBINGLURAAS® (护固莱士®) - Human Fibrin Sealant Kit Fibrin sealant used as topical hemostatic agent for surgical bleeding control. Recognized as 2025 Shanghai Manufacturing Single Champion Product.
• THROMBIRAAS® (舒平莱士®) - Human Thrombin Topical thrombin used as a hemostatic agent in surgical procedures.
• SR604 Injection - Activated Protein C Monoclonal Antibody Globally first-in-class monoclonal antibody drug targeting activated protein C for prophylactic treatment of bleeding in hemophilia and congenital factor VII deficiency. Administered subcutaneously every 4-8 weeks; Phase I/II trials show >90% reduction in annualized bleeding rate at 0.4mg/kg dose. Currently in clinical development (Phase II/III).

Quantifiable outcome

• SR604 reduces annualized bleeding rate by over 90% with subcutaneous injection every 4-8 weeks at 0.4mg/kg dose in Phase I/II clinical trials
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Nanyue Biological Products Co., Ltd. (南岳生物制药有限公司)coreOthers · 31 March 2025Shanghai RAAS announced acquisition of 100% equity of Nanyue Biological for RMB 4.2 billion. Nanyue is Hunan Province's sole blood product manufacturer with 9 operational plasma stations, 2024 plasma collection of 278 tons, and design capacity of 500 tons. The acquisition will add 18%+ growth to Shanghai RAAS's plasma collection volume and expand the group's market presence in Central China.
• Grifols (基立福)coreStrategic or Co-development Partner · 18 June 2024Following Haier's acquisition, Grifols retained a 6.58% stake and a board seat in Shanghai RAAS. A comprehensive exclusive strategic cooperation agreement was signed covering production and quality management, exclusive distribution, R&D and innovation activities for all Grifols' existing and future China business. The existing albumin distribution agreement was extended for up to 20 years. Shanghai RAAS also became the exclusive distributor of Grifols' Procleix NAT product portfolio in mainland China.
• Boehringer-Ingelheim (勃林格殷格翰)coreStrategic or Co-development Partner · 13 March 2024Boehringer-Ingelheim Biopharmaceuticals (China) provides Shanghai RAAS with full-process CDMO services for SR604 injection, including process transfer, drug substance and drug product cGMP manufacturing, and CMC filing document writing. The partnership aims to bring the innovative hemophilia drug to Chinese patients and benefit global patients, helping Chinese innovation go overseas.
• Grifols (Procleix NAT Distribution)coreChannel Partner/ Reseller/ Distributor · 15 April 2022Shanghai RAAS and its subsidiaries (Tonrol Biopharmaceutical, Anhui Tonrol Medicine, Zhengzhou RAAS, Zhejiang Haikang) became the exclusive distributor of Grifols' Procleix nucleic acid testing product portfolio in mainland China. The partnership covers Grifols' Procleix Panther System using TMA technology for blood and plasma screening of HIV-1, HIV-2, HCV, and HBV.

Scale indicators12 records

Recent moves10 records

Expansion highlights6 records

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/shanghai-raas-blood-products-co.-ltd.

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries5 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shanghai Raas Blood Products